DiscoveryProbe™ FDA-approved Drug Library: Enabling High-Throughput Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) offers 2,320 bioactive compounds, each clinically approved by major agencies such as FDA, EMA, HMA, CFDA, and PMDA (product page). Compounds are supplied as 10 mM DMSO solutions, validated for up to 24 months at -80°C. This resource enables reproducible high-throughput and high-content screening for drug repositioning and mechanistic discovery (HDAC4.com). Representative drugs such as doxorubicin, metformin, and atorvastatin cover diverse pharmacological mechanisms. The library supports research into signaling pathways, neurodegenerative disease models, and cancer pharmacology (Yin et al., 2022).

Biological Rationale

Drug discovery increasingly leverages libraries of clinically validated compounds to streamline translational research. The DiscoveryProbe™ FDA-approved Drug Library contains bioactive molecules spanning receptor agonists, antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators (ApexBio). Such libraries enable the systematic interrogation of cellular response networks, including cAMP/PKA, CREB, and MAPK pathways implicated in cell growth, synaptic plasticity, and proteostasis (Yin et al., 2022). This approach accelerates the identification of compounds with therapeutic potential for complex diseases like cancer and neurodegeneration, where pathway cross-talk and redundancy complicate traditional discovery workflows.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library encompasses diverse compound classes, including:

• Receptor agonists/antagonists: Modulate G protein-coupled receptors (GPCRs), nuclear receptors, and neurotransmitter systems.
• Enzyme inhibitors: Target kinases (e.g., JNK, MAPK), proteasome subunits, and metabolic enzymes (e.g., metformin for AMPK activation).
• Ion channel modulators: Influence calcium, potassium, or sodium flux, impacting excitability and signal transduction.
• Signal pathway regulators: Affect cAMP/PKA, Akt, and CREB axes, critical in stress response and protein homeostasis (Yin et al., 2022).

High-throughput and high-content screens using this library allow systematic annotation of compound effects on cellular phenotypes. For example, proteasome inhibitors in the library have been shown to robustly increase CREB activity in Drosophila models via JNK-mediated phosphorylation, linking pharmacological action to transcriptional regulation and proteotoxic stress adaptation (Yin et al., 2022).

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 compounds, all clinically approved or pharmacopoeia-listed, supporting broad regulatory relevance (ApexBio).
• Each compound is supplied as a pre-dissolved 10 mM DMSO stock, stable for 12 months at -20°C and up to 24 months at -80°C (ApexBio).
• High-throughput screening using this library identified all proteasome inhibitors as CREB activators in vivo, mediated by ROS/JNK signaling (Yin et al., 2022, DOI).
• CRTC overexpression in muscle restored proteasomal activity and ameliorated Huntington’s disease phenotypes in Drosophila (Yin et al., 2022, DOI).
• The library supports robust drug repositioning and pharmacological target identification workflows as validated across multiple internal and external studies (PrecisionFDA).

For an expanded workflow and troubleshooting guide, see the article 'DiscoveryProbe FDA-approved Drug Library: Powering Next-G...', which this article extends by providing updated mechanistic links to CREB signaling and oxidative stress adaptation.

Applications, Limits & Misconceptions

Applications:

• Drug repositioning screens to uncover novel indications for existing compounds.
• Pharmacological target identification in cancer cell lines, neurodegenerative disease models, and primary cells (B-Pompilidotoxin.com).
• Signal pathway mapping, including CREB and JNK axes, using mechanism-guided compound pools.
• Validation of high-content imaging-based phenotypic screens with clinically actionable compounds.
• Structure-activity relationship (SAR) analysis using well-characterized clinical molecules.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for in vivo applications: The library is formulated for in vitro and cell-based assays; in vivo use requires additional validation and may be limited by DMSO toxicity.
• The library does not cover investigational or preclinical compounds: Only FDA/EMA/HMA/CFDA/PMDA-approved or pharmacopeia-listed drugs are included.
• Solubility is optimized for DMSO, not aqueous buffers: Direct addition to aqueous systems may result in precipitation or reduced bioavailability.
• Concentration-dependent effects must be calibrated: 10 mM stocks require careful dilution; off-target effects are possible at high concentrations.
• Not a substitute for genetic validation: Pharmacological findings should be corroborated with orthogonal genetic or molecular approaches (HDAC4.com extends the structured screening protocol but does not address these limitations).

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is compatible with high-throughput screening (HTS) and high-content screening (HCS) platforms. Compounds are arrayed in 96-well microplates, deep-well plates, or 2D barcoded screw-top tubes, supporting automation and tracking. Each well contains a 10 mM DMSO solution. Plates are shipped on blue ice for evaluation samples and at room temperature or blue ice for bulk orders. Users should store plates at -20°C or -80°C for maximum stability.

Integration Steps:

1. Thaw plates at room temperature; avoid repeated freeze-thaw cycles.
2. Design screening assays for physiologically relevant concentrations (e.g., <2% final DMSO in cell culture).
3. Validate hits with secondary dose-response and orthogonal assays.
4. Use internal controls and replicate wells to ensure reproducibility.

For more detailed workflow strategies and troubleshooting, see 'From Mechanism to Medicine: How the DiscoveryProbe™ FDA-a...'. This article updates that content by mapping new evidence for the CREB/CRTC axis in stress adaptation.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) represents a gold standard resource for translational research, enabling high-throughput drug repositioning, pharmacological target identification, and mechanistic pathway elucidation. Its rigorously curated, stable, and automation-friendly format supports reproducible screening in oncology, neurodegeneration, and signaling studies. Ongoing research continues to reveal novel applications, such as the modulation of CREB and JNK signaling in models of proteostasis and aging (Yin et al., 2022). For structured screening protocols, see 'DiscoveryProbe™ FDA-approved Drug Library: Structured Scr...', which this article clarifies by linking mechanistic outcomes with compound benchmarks. For ordering and detailed specifications, refer to the DiscoveryProbe™ FDA-approved Drug Library product page.